Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
Notified -
Globe Newswire3-12-2025, 20:00
Clean Core Thorium Energy Raises $15.5M in Series Seed 6-02-2025, 22:43